Ask about this productRelated genes to: ZNF154 antibody
- Gene:
- ZNF154 NIH gene
- Name:
- zinc finger protein 154
- Previous symbol:
- -
- Synonyms:
- pHZ-92
- Chromosome:
- 19q13.43
- Locus Type:
- gene with protein product
- Date approved:
- 1994-03-16
- Date modifiied:
- 2016-10-05
Related products to: ZNF154 antibody
Related articles to: ZNF154 antibody
- - Source: PubMed
Publication date: 2025/12/08
Lin ShuyeYan XiangxiuZhu LingqinMen FangliYang LangZheng QinghuaZhang HuanTian QifeiYu JianweiSheng JianqiuYi XiangGuo WeiCui YingxiangHe Yuqi - Recent studies show that patients with Alzheimer's disease (AD) harbor specific methylation marks in the brain that, if accessible, could be used as epigenetic biomarkers. Liquid biopsy enables the study of circulating cell-free DNA (cfDNA) fragments originated from dead cells, including neurons affected by neurodegenerative processes. Here, we isolated and epigenetically characterized plasma cfDNA from 35 patients with AD and 35 cognitively healthy controls by using the Infinium MethylationEPIC BeadChip array. Bioinformatics analysis was performed to identify differential methylation positions (DMPs) and regions (DMRs), including ε4 genotype stratified analysis. Plasma pTau181 (Simoa) and cerebrospinal fluid (CSF) core biomarkers (Fujirebio) were also measured and correlated with differential methylation marks. Validation was performed with bisulfite pyrosequencing and bisulfite cloning sequencing. Epigenome-wide cfDNA analysis identified 102 DMPs associated with AD status. Most DMPs correlated with clinical cognitive and functional tests including 60% for Mini-Mental State Examination (MMSE) and 80% for Global Deterioration Scale (GDS), and with AD blood and CSF biomarkers. In silico functional analysis connected 30 DMPs to neurological processes, identifying key regulators such as and genes. Several DMRs were annotated to genes previously reported to harbor epigenetic brain changes in AD (, , , , , ) and were linked to ε4 genotypes. Notably, a DMR in the gene, previously shown to be hypermethylated in the AD hippocampus, was validated in cfDNA from an orthogonal perspective. These results support the feasibility of studying cfDNA to identify potential epigenetic biomarkers in AD. Thus, liquid biopsy could improve non-invasive AD diagnosis and aid personalized medicine by detecting epigenetic brain markers in blood. - Source: PubMed
Publication date: 2025/04/05
Macías MónicaAlba-Linares Juan JoséAcha BlancaBlanco-Luquin IdoiaFernández Agustín FÁlvarez-Jiménez JohanaUrdánoz-Casado AmayaRoldan MirenRobles MaitaneCabezon-Arteta EnekoAlcolea DanielGordoa Javier Sánchez Ruiz deCorroza JonCabello CarolinaErro María ElenaJericó IvonneFraga Mario FMendioroz Maite - Diagnosis of primary and relapsed bladder carcinomas is accomplished by urethrocystoscopy, an invasive procedure, combined with urinary cytology, with limited sensitivity, resulting in a substantial burden. Thus, noninvasive biomarkers have been investigated, among which DNA methylation has shown promise. This systematic review and meta-analysis sought to assess the diagnostic accuracy of DNA methylation biomarkers reported in the literature for bladder cancer detection, pinpointing the most informative one. - Source: PubMed
Publication date: 2024/06/19
Silva-Ferreira MarianaCarvalho João ASalta SofiaHenriques Teresa SPereira Rodrigues PedroMonteiro-Reis SaraHenrique RuiJerónimo Carmen - Analysis of cell-free DNA methylation (cfDNAme), alone or combined with CA125, could help to detect ovarian cancers earlier and may reduce mortality. We assessed cfDNAme in regions of ZNF154, C2CD4D and WNT6 via targeted bisulfite sequencing in diagnostic and early detection (preceding diagnosis) settings. Diagnostic samples were obtained via prospective blood collection in cell-free DNA tubes in a convenience series of patients with a pelvic mass. Early detection samples were matched case-control samples derived from the UK Familial Ovarian Cancer Screening Study (UKFOCSS). In the diagnostic set (n = 27, n = 41), the specificity of cfDNAme was 97.6% (95% CI: 87.1%-99.9%). High-risk cancers were detected with a sensitivity of 80% (56.3%-94.3%). Combination of cfDNAme and CA125 resulted in a sensitivity of 94.4% (72.7%-99.9%) for high-risk cancers. Despite technical issues in the early detection set (n = 29, n = 29), the specificity of cfDNAme was 100% (88.1%-100.0%). We detected 27.3% (6.0%-61.0%) of high-risk cases with relatively lower genomic DNA (gDNA) contamination. The sensitivity rose to 33.3% (7.5%-70.1%) in samples taken <1 year before diagnosis. We detected ovarian cancer in several patients up to 1 year before diagnosis despite technical limitations associated with archival samples (UKFOCSS). Combined cfDNAme and CA125 assessment may improve ovarian cancer screening in high-risk populations, but future large-scale prospective studies will be required to validate current findings. - Source: PubMed
Publication date: 2023/10/20
Herzog ChiaraJones AllisonEvans IonaReisel DanielOlaitan AdeolaDoufekas KonstantinosMacDonald NicolaRådestad Angelique FlöterGemzell-Danielsson KristinaZikan MichalCibula DavidDostálek LukášPaprotka TobiasLeimbach AndreasSchmitt MarkusRyan AndyGentry-Maharaj AleksandraApostolidou SophiaRosenthal Adam NMenon UshaWidschwendter Martin - The ability to detect several types of cancer using a non-invasive, blood-based test holds the potential to revolutionize oncology screening. We mined tumor methylation array data from the Cancer Genome Atlas (TCGA) covering 14 cancer types and identified two novel, broadly-occurring methylation markers at and . To evaluate their performance as a generalized blood-based screening approach, along with our previously reported methylation biomarker, , we rigorously assessed each marker individually or combined. Utilizing TCGA methylation data and applying logistic regression models within each individual cancer type, we found that the three-marker combination significantly increased the average area under the ROC curve (AUC) across the 14 tumor types compared to single markers ( = 1.158 × 10; Friedman test). Furthermore, we simulated dilutions of tumor DNA into healthy blood cell DNA and demonstrated increased AUC of combined markers across all dilution levels. Finally, we evaluated assay performance in bisulfite sequenced DNA from patient tumors and plasma, including early-stage samples. When combining all three markers, the assay correctly identified nine out of nine lung cancer plasma samples. In patient plasma from hepatocellular carcinoma, alone yielded the highest combined sensitivity and specificity values averaging 68% and 72%, whereas multiple markers could achieve higher sensitivity or specificity, but not both. Altogether, this study presents a comprehensive pipeline for the identification, testing, and validation of multi-cancer methylation biomarkers with a considerable potential for detecting a broad range of cancer types in patient blood samples. - Source: PubMed
Publication date: 2023/10/01
Funderburk KarenBang-Christensen Sara RMiller Brendan FTan HuaMargolin GennadyPetrykowska Hanna MBaugher CatherineFarney S KatieGrimm Sara AJameel NaderHolland David OAltman Naomi SElnitski Laura